Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 55 results
Sort by:
Filters: Keyword is Reverse Transcriptase Inhibitors  [Clear All Filters]
Found 55 results.
  Print   CSV
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

A

Valcour V, Yeh T-M, Bartt R, et al. "Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection." HIV Med.. 2009;10(2):103-10.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Gripshover BM, Ribaudo H, Santana J, et al. "Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118)." Antivir. Ther. (Lond.). 2006;11(5):619-23.
Zheng Y, Hughes MD, Lockman S, et al. "Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens." Clin. Infect. Dis.. 2014;59(6):888-96.

B

Huang JS, Hughes MD, Riddler SA, Haubrich RH. "Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142." HIV Clin Trials. 2013;14(5):224-34.

C

Brown TT, Moser C, Currier JS, et al. "Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir." J. Infect. Dis.. 2015;212(8):1241-9.
McComsey GA, Daar ES, O'Riordan MA, et al. "Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202." J. Infect. Dis.. 2013;207(4):604-11.
Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. "Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment." J. Acquir. Immune Defic. Syndr.. 2006;43(4):433-5.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Paredes R, Tzou PL, van Zyl G, et al. "Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation." PLoS ONE. 2017;12(7):e0181357.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.
Ribaudo HJ, Kuritzkes DR, Gulick RM. "A comparison of three initial antiretroviral AIDS regimens." N. Engl. J. Med.. 2007;357(10):1056-7.

D

Cohn SE, Park J-G, Watts DH, et al. "Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions." Clin. Pharmacol. Ther.. 2007;81(2):222-7.
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. "Design issues in initial HIV-treatment trials: focus on ACTG A5095." Antivir. Ther. (Lond.). 2006;11(6):751-60.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Snoeck J, Kantor R, Shafer RW, et al. "Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent." Antimicrob. Agents Chemother.. 2006;50(2):694-701.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.

E

Podany AT, Bao Y, Swindells S, et al. "Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention." Clin. Infect. Dis.. 2015;61(8):1322-7.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Ribaudo HJ, Liu H, Schwab M, et al. "Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study." J. Infect. Dis.. 2010;202(5):717-22.
Lennox JL, Landovitz RJ, Ribaudo HJ, et al. "Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial." Ann. Intern. Med.. 2014;161(7):461-71.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Hulgan T, Haubrich R, Riddler SA, et al. "European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142." AIDS. 2011;25(1):37-47.

H

Tashima KT, Smeaton LM, Fichtenbaum CJ, et al. "HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial." Ann. Intern. Med.. 2015;163(12):908-17.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Haas DW. "Human genetic variability and HIV treatment response." Curr HIV/AIDS Rep. 2006;3(2):53-8.

I

Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.
Aweeka FT, Rosenkranz SL, Segal Y, et al. "The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine." AIDS. 2006;20(14):1833-41.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.

Pages